BAKER BROS. ADVISORS LP Q1 2020 Filing
Filed May 15, 2020
Portfolio Value
$16.2B
Holdings
110
Report Date
Q1 2020
Filing Type
13F-HR
All Holdings (110 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | AUTLAutolus Therapeutics plc | 156,773 | $939.0M | 5.78% | |
| 102 | GLMDGalmed Pharmaceuticals Ltd. | 215,594 | $746.0M | 4.59% | |
| 103 | IDYAIDEAYA Biosciences, Inc. | 126,611 | $522.0M | 3.22% | |
| 104 | —Adamas Pharmaceuticals, Inc. | 172,630 | $499.0M | 3.07% | |
| 105 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $486.0M | 2.99% | |
| 106 | GNFTYGenfit SA | 26,696 | $395.0M | 2.43% | |
| 107 | —Affimed N.V. | 200,000 | $316.0M | 1.95% | |
| 108 | —Sunesis Pharmaceuticals, Inc. | 556,665 | $231.0M | 1.42% | |
| 109 | OVIDOvid Therapeutics Inc. | 69,471 | $207.0M | 1.27% | |
| 110 | CTMXCytomX Therapeutics, Inc. | 20,000 | $153.0M | 0.94% |
PreviousPage 2 of 2